Ask VL: Attorney Wyatt Berkover Discusses Asbestos Litigation

April 18, 2019 By swarren

When it comes to asbestos litigation, it is crucial to work with a firm that has extensive knowledge of the industry. Chicago’s Vogelzang Law is a boutique law firm dedicated to families and individuals facing a mesothelioma diagnosis. Attorney Wyatt Berkover sat down to discuss some of his proudest moments: Q: What should more people…

Nicholas Vogelzang Presents at Perrin Conferences

March 21, 2019 By Nicholas Vogelzang

I was recently given the opportunity to speak at the Perrin Cutting-Edge Issues in Asbestos Litigation Conference in Beverly Hills, California. This conference is unique in that, unlike most conferences for lawyers involved in a particular area of litigation, it brings together lawyers representing both sides, in addition to insurance carriers that ultimately pay the…

New Year, New Office Space for Vogelzang Law

January 31, 2019 By swarren

As the new year begins, the Vogelzang Law team is settling into its new office space overlooking bustling Michigan Avenue. The firm’s expanded offices are home to an ever-expanding team, as the boutique firm continues to grow and serve families affected by mesothelioma. The renovations, which began in mid-2018, extended the Vogelzang Law offices from 5,000…

Tuesday Asbestos Call Recap: Vogelzang Law Compels Deposition & is Granted a ‘Finding of Default’ Motion

February 27, 2018 By Nikoleta Morales

Chicago, IL, February 23 at the Daley Center – Vogelzang Law celebrated yet another victory last week. Attorney Wyatt J. Berkover from Vogelzang Law represents the estate of Roger Nelson, plaintiff, who passed away from mesothelioma.  Mr. Nelson was exposed to numerous asbestos-containing products while working as a sheet metal worker leading to his diagnosis…

Vogelzang Law News

UNIVERSITY OF CHICAGO MESOTHELIOMA DRUG TRIALS NEW HOPE FOR MESOTHELIOMA PATIENTS

July 29, 2016 By Vogelzang Law Webmaster

A clinical study of malignant pleural mesothelioma patients treated with investigational cancer vaccine CRS-207 at University of Chicago Medical Center, UCSF’s cancer center, the Moffitt Cancer Center in Tampa, the Abramson Cancer Center in Philadelphia and the National Cancer Institutein Bethesda, Maryland has shown promising results in shrinking tumors. CRS-207 caused tumor shrinkage in 85% of…